ImmuneOnco and Instil Bio’s PD-L1xVEGF Bispecific Antibody Shows Promising Results in Phase 2 Lung Cancer Trial

ImmuneOnco and Instil Bio announced encouraging preliminary results from a Phase 2 trial of IMM2510/AXN-2510, a PD-L1xVEGF bispecific antibody, in combination with chemotherapy for front-line non-small cell lung cancer (NSCLC) in China13.

The trial demonstrated a partial response rate of 62% overall, with a notably high 80% response rate in patients with squamous NSCLC and 46% in non-squamous NSCLC1.

Among 33 patients treated at the 10 mg/kg dose, the combination was well-tolerated with no dose-limiting toxicities and minimal serious adverse events13.

IMM2510/AXN-2510 is considered differentiated from other PD-(L)1xVEGF bispecifics by its broader VEGF trapping mechanism and enhanced antibody-dependent cellular cytotoxicity (ADCC)3.

Both companies plan to advance to Phase 3 studies in China and to initiate a Phase 1 trial in the United States by the end of 2025123.

This antibody is under development to address solid tumors more broadly, with the aim of establishing best-in-class efficacy among PD-(L)1xVEGF agents23.

Sources:

1. https://www.stocktitan.net/news/TIL/immune-onco-announced-preliminary-safety-efficacy-data-from-the-xmsvx7ntg8e8.html

2. https://www.nasdaq.com/articles/instil-bio-and-immuneonco-announce-phase-2-trial-update-2510-nsclc-and-planned-us-trial

3. https://www.globenewswire.com/news-release/2025/07/31/3124761/0/en/ImmuneOnco-Announced-Preliminary-Safety-Efficacy-Data-from-the-Clinical-Trial-Studying-IMM2510-AXN-2510-a-PD-L1xVEGF-Bispecific-Antibody-in-Combination-with-Chemotherapy-in-Front-l.html